Holen Sie sich die Stockscreener-App
2.02
2.18%
-0.045
Handel nachbörslich:
2.15
0.13
+6.44%
Schlusskurs vom Vortag:
$2.065
Offen:
$2.07
24-Stunden-Volumen:
2.43M
Relative Volume:
1.68
Marktkapitalisierung:
$188.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.6121
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
-15.83%
1M Leistung:
-0.98%
6M Leistung:
-5.61%
1J Leistung:
-5.61%
1-Tages-Spanne:
$1.95
$2.08
1-Wochen-Bereich:
$1.95
$2.51
52-Wochen-Spanne:
$0.783
$3.39
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(858) 945-2393
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.02 | 188.58M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance
Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com
Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener
Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com
Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo
Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch
Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha
Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView
Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India
VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus
Piper Sandler maintains $21 target on Ventyx stock By Investing.com - Investing.com Nigeria
Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX) - Defense World
Ventyx Biosciences reports annual meeting results By Investing.com - Investing.com South Africa
Ventyx Biosciences reports annual meeting results - Investing.com
Piper Sandler maintains $21 target on Ventyx stock - Investing.com
As Ventyx Approaches Multiple Phase II Readouts, What Could Be Next For The Stock? - RTTNews
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Squarepoint Ops LLC - Defense World
Two Sigma Investments LP Has $1.04 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences at Jefferies Conference: Strategic Developments in Focus By Investing.com - Investing.com Canada
Millennium Management LLC Purchases 1,008,760 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Northern Trust Corp Buys 19,982 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Ventyx Biosciences Executives Set for Key Presentation on Autoimmune Drug Pipeline at Jefferies Conference - Stock Titan
BNP Paribas Financial Markets Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Bank of America Corp DE Has $9.36 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Spotlight On 3 Penny Stocks With Market Caps Under $500M - simplywall.st
VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Price T Rowe Associates Inc. MD Sells 13,616 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Dimensional Fund Advisors LP Makes New $347,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Barclays PLC Boosts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Mariner LLC Sells 8,485 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Ventyx Biosciences Reports Q1 2025 Financial Results - TipRanks
Investors who lost money on Ventyx Biosciences, Inc. (VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Lost Money on Ventyx Biosciences, Inc.(VTYX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders of Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Market Resilience: Ventyx Biosciences Inc (VTYX) Finishes Weak at 1.28, Down -5.88 - DWinneX
Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc. - ACCESS Newswire
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress - The Manila Times
Ratios Uncovered: Breaking Down Ventyx Biosciences Inc (VTYX)’s Trailing Twelve Months Metrics - DWinneX
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ventyx Biosciences Inc-Aktie (VTYX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Mar 28 '25 |
Option Exercise |
0.00 |
11,844 |
0 |
2,303,540 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Mar 28 '25 |
Option Exercise |
0.00 |
4,531 |
0 |
469,113 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 27 '24 |
Sale |
2.36 |
21,119 |
49,841 |
464,582 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):